Its role in TTR-CM-related cardiomyopathy has not been well described and may offer symptomatic benefit when conventional therapies are insufficient.<h4>Take-home message</h4>BAT may be a useful adjunctive therapy to improve symptoms and quality of life in selected patients with TTR-CM and refractory heart failure. This evidence concerns the gene TTR and cutaneous mastocytosis.